Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?



Status:Recruiting
Conditions:Breast Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:10/31/2018
Start Date:November 2014
End Date:November 2019
Contact:Gary Ulaner, MD, PhD
Phone:212-639-3776

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
Some breast cancer cells make a protein called Human Epidermal Growth factor receptor 2
(HER2). Patients with HER2 positive (HER2+) breast cancer receive medicine that attacks HER2,
which helps these patients live longer. Some HER2 negative (HER2-) breast cancer patients
also benefit from medicines that attack HER2, but we do not know why or which patients will
benefit. This study uses a new imaging method, HER2-targeted PET/CT, to identify patients
that may benefit from medicines that attack HER2. This is experimental.


Inclusion Criteria:

- Women age > 18

- Biopsy proven HER2 negative primary breast cancer and biopsy proven metastatic
disease.

- 5 or more foci of demonstrable metastases on recent imaging modalities (CT, MR, FDG
PET/CT)

- ECOG performance score of 0-2

Exclusion Criteria:

- Life expectancy < 3months

- Pregnancy or lactation

- Patients who cannot undergo PET/CT scanning because of weight limits

- CNS only disease on recent imaging
We found this trial at
1
site
Memorial Sloan Kettering Cancer Center
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Gary Ulaner, MD, PhD
Phone: 212-639-3776
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials